Dehydroepiandrosterone in Fibrotic Interstitial Lung Disease: a Translational Study

Overview

Journal Respir Res

Specialty Pulmonary Medicine

Date 2022 Jun 8

PMID 35676709

Authors

Sabina A Guler

Carlos Machahua

Thomas K Geiser

Gregor Kocher

Thomas M Marti

Benjamin Tan

Verdiana Trappetti

Christopher J Ryerson

Manuela Funke-Chambour

Affiliations

Soon will be listed here.

Abstract

Background: Dehydroepiandrosterone (DHEA) is a precursor sex hormone with antifibrotic properties. The aims of this study were to investigate antifibrotic mechanisms of DHEA, and to determine the relationship between DHEA-sulfate (DHEAS) plasma levels, disease severity and survival in patients with fibrotic interstitial lung diseases (ILDs).

Methods: Human precision cut lung slices (PCLS) and normal human lung fibroblasts were treated with DHEA and/or transforming growth factor (TGF)-β1 before analysis of pro-fibrotic genes and signal proteins. Cell proliferation, cytotoxicity, cell cycle and glucose-6-phosphate dehydrogenase (G6PD) activity were assessed. DHEAS plasma levels were correlated with pulmonary function, the composite physiologic index (CPI), and time to death or lung transplantation in a derivation cohort of 31 men with idiopathic pulmonary fibrosis (IPF) and in an independent validation cohort of 238 men and women with fibrotic ILDs.

Results: DHEA decreased the expression of pro-fibrotic markers in-vitro and ex-vivo. There was no cytotoxic effect for the applied concentrations, but DHEA interfered in proliferation by modulating the cell cycle through reduction of G6PD activity. In men with IPF (derivation cohort) DHEAS plasma levels in the lowest quartile were associated with poor lung function and higher CPI (adjusted OR 1.15 [95% CI 1.03-1.38], p = 0.04), which was confirmed in the fibrotic ILD validation cohort (adjusted OR 1.03 [95% CI 1.00-1.06], p = 0.01). In both cohorts the risk of early mortality was higher in patients with low DHEAS levels, after accounting for potential confounding by age in men with IPF (HR 3.84, 95% CI 1.25-11.7, p = 0.02), and for age, sex, IPF diagnosis and prednisone treatment in men and women with fibrotic ILDs (HR 3.17, 95% CI 1.35-7.44, p = 0.008).

Conclusions: DHEA reduces lung fibrosis and cell proliferation by inducing cell cycle arrest and inhibition of G6PD activity. The association between low DHEAS levels and disease severity suggests a potential prognostic and therapeutic role of DHEAS in fibrotic ILD.

Citing Articles

Fibrosis in PCLS: comparing TGF-β and fibrotic cocktail.

Machahua C, Marti T, Dorn P, Funke-Chambour M Respir Res. 2025; 26(1):44.

PMID: 39875887 PMC: 11776118. DOI: 10.1186/s12931-025-03110-2.

Precision Cut Lung Slices: Emerging Tools for Preclinical and Translational Lung Research. An Official American Thoracic Society Workshop Report.

Lehmann M, Krishnan R, Sucre J, Kulkarni H, Pineda R, Anderson C Am J Respir Cell Mol Biol. 2024; .

PMID: 39499861 PMC: 11707673. DOI: 10.1165/rcmb.2024-0479ST.

Analysis of Endocrine and Inflammatory Markers in Preserved Ratio Impaired Spirometry.

Jesus F, Santiago Moraes A, Neves da Silva I, Passos F, Salles C, Neves M Med Sci (Basel). 2024; 12(2).

PMID: 38651412 PMC: 11036252. DOI: 10.3390/medsci12020018.

Frontal Fibrosing Alopecia and Reproductive Health: Assessing the Role of Sex Hormones in Disease Development.

Roman A, Petca R, Dumitrascu M, Petca A, Ionescu Miron A, Sandru F J Pers Med. 2024; 14(1).

PMID: 38248773 PMC: 10817300. DOI: 10.3390/jpm14010072.

Changes of androgen and corticosterone metabolites excretion and conversion in cystic fibrosis.

Podgorski R, Suminska M, Rachel M, Pikula B, Fichna P, Bidlingmaier M Front Endocrinol (Lausanne). 2023; 14:1244127.

PMID: 37711888 PMC: 10497873. DOI: 10.3389/fendo.2023.1244127.

References

Yang H, Wu Y, Yen W, Liu H, Hwang T, Stern A . The Redox Role of G6PD in Cell Growth, Cell Death, and Cancer. Cells. 2019; 8(9). PMC: 6770671. DOI: 10.3390/cells8091055. View

Hashimoto R, Lanier G, Dhagia V, Joshi S, Jordan A, Waddell I . Pluripotent hematopoietic stem cells augment α-adrenergic receptor-mediated contraction of pulmonary artery and contribute to the pathogenesis of pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2020; 318(2):L386-L401. PMC: 7052680. DOI: 10.1152/ajplung.00327.2019. View

Suzuki T, Carrier E, Talati M, Rathinasabapathy A, Chen X, Nishimura R . Isolation and characterization of endothelial-to-mesenchymal transition cells in pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol. 2017; 314(1):L118-L126. PMC: 5866427. DOI: 10.1152/ajplung.00296.2017. View

Snetselaar R, van Moorsel C, Kazemier K, van der Vis J, Zanen P, van Oosterhout M . Telomere length in interstitial lung diseases. Chest. 2015; 148(4):1011-1018. DOI: 10.1378/chest.14-3078. View

Jia C, Chen X, Li X, Li M, Miao C, Sun B . The effect of DHEA treatment on the oxidative stress and myocardial fibrosis induced by Keshan disease pathogenic factors. J Trace Elem Med Biol. 2011; 25(3):154-9. DOI: 10.1016/j.jtemb.2011.04.001. View

Raghu G, Remy-Jardin M, Myers J, Richeldi L, Ryerson C, Lederer D . Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018; 198(5):e44-e68. DOI: 10.1164/rccm.201807-1255ST. View

Behr J, Prasse A, Kreuter M, Johow J, Rabe K, Bonella F . Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med. 2021; 9(5):476-486. DOI: 10.1016/S2213-2600(20)30554-3. View

Tieche C, Peng R, Dorn P, Froment L, Schmid R, Marti T . Prolonged pemetrexed pretreatment augments persistence of cisplatin-induced DNA damage and eliminates resistant lung cancer stem-like cells associated with EMT. BMC Cancer. 2016; 16:125. PMC: 4759918. DOI: 10.1186/s12885-016-2117-4. View

Iwasaki T, Mukasa K, Yoneda M, Ito S, Yamada Y, Mori Y . Marked attenuation of production of collagen type I from cardiac fibroblasts by dehydroepiandrosterone. Am J Physiol Endocrinol Metab. 2005; 288(6):E1222-8. DOI: 10.1152/ajpendo.00370.2004. View

10.

Zapata E, Ventura J, De la Cruz K, Rodriguez E, Damian P, Masso F . Dehydroepiandrosterone inhibits the proliferation of human umbilical vein endothelial cells by enhancing the expression of p53 and p21, restricting the phosphorylation of retinoblastoma protein, and is androgen- and estrogen-receptor independent. FEBS J. 2005; 272(6):1343-53. DOI: 10.1111/j.1742-4658.2005.04563.x. View

11.

Wanger J, Clausen J, Coates A, Pedersen O, Brusasco V, Burgos F . Standardisation of the measurement of lung volumes. Eur Respir J. 2005; 26(3):511-22. DOI: 10.1183/09031936.05.00035005. View

12.

Levy M, Waters A, Sen S, Castel A, Plankey M, Molock S . Psychosocial stress and neuroendocrine biomarker concentrations among women living with or without HIV. PLoS One. 2021; 16(12):e0261746. PMC: 8699620. DOI: 10.1371/journal.pone.0261746. View

13.

Ventetuolo C, Baird G, Barr R, Bluemke D, Fritz J, Hill N . Higher Estradiol and Lower Dehydroepiandrosterone-Sulfate Levels Are Associated with Pulmonary Arterial Hypertension in Men. Am J Respir Crit Care Med. 2015; 193(10):1168-75. PMC: 4872665. DOI: 10.1164/rccm.201509-1785OC. View

14.

Alsafadi H, Staab-Weijnitz C, Lehmann M, Lindner M, Peschel B, Konigshoff M . An ex vivo model to induce early fibrosis-like changes in human precision-cut lung slices. Am J Physiol Lung Cell Mol Physiol. 2017; 312(6):L896-L902. DOI: 10.1152/ajplung.00084.2017. View

15.

Bonnet S, Dumas-de-la-Roque E, Begueret H, Marthan R, Fayon M, Santos P . Dehydroepiandrosterone (DHEA) prevents and reverses chronic hypoxic pulmonary hypertension. Proc Natl Acad Sci U S A. 2003; 100(16):9488-93. PMC: 170945. DOI: 10.1073/pnas.1633724100. View

16.

Bonnet S, Paulin R, Sutendra G, Dromparis P, Roy M, Watson K . Dehydroepiandrosterone reverses systemic vascular remodeling through the inhibition of the Akt/GSK3-{beta}/NFAT axis. Circulation. 2009; 120(13):1231-40. DOI: 10.1161/CIRCULATIONAHA.109.848911. View

17.

Hashimoto N, Phan S, Imaizumi K, Matsuo M, Nakashima H, Kawabe T . Endothelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 2009; 43(2):161-72. PMC: 2937229. DOI: 10.1165/rcmb.2009-0031OC. View

18.

Yoshida S, Honda A, Matsuzaki Y, Fukushima S, Tanaka N, Takagiwa A . Anti-proliferative action of endogenous dehydroepiandrosterone metabolites on human cancer cell lines. Steroids. 2002; 68(1):73-83. DOI: 10.1016/s0039-128x(02)00117-4. View

19.

Ryerson C, Vittinghoff E, Ley B, Lee J, Mooney J, Jones K . Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest. 2013; 145(4):723-728. DOI: 10.1378/chest.13-1474. View

20.

Tokushige K, Hashimoto E, Kodama K, Tobari M, Matsushita N, Kogiso T . Serum metabolomic profile and potential biomarkers for severity of fibrosis in nonalcoholic fatty liver disease. J Gastroenterol. 2013; 48(12):1392-400. PMC: 3889284. DOI: 10.1007/s00535-013-0766-5. View